Australia's Imugene climbs on ethics approval for cancer treatment trial

Imugene

09/01/2023 24:46

** Shares of Imugene  IMU.AX  rise as much as 7.8% to
A$0.173, hitting their highest since Jan 5
    ** The cancer-focused biopharma co receives Human Research
Ethics Committee approval to start a Phase I clinical trial of
its oncolytic virotherapy candidate, Vaxinia, in Australia
 urn:newsml:reuters.com:*:nFWN33R2I0
    ** Co says Vaxinia will be used to treat patients with
metastatic or advanced solid tumours
    ** IMU stock lost 63.8% in 2022
 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))